A multivariate proportional hazard model was used to evaluate the prognostic relevance of the expression of ICOSL after being adjusted for the following clinical prognostic factors: age, AJCC cancer stage, histologic type, histology grade ER, progesterone (PR), and HER2 (Table 3). This evidence concerns the gene ERBB2 and cancer.